In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 104 days of free consultation

 

Circulating galectin 1 is associated with severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography

Session Poster Session 6

Speaker Ruey-Hsing Chou

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Inflammation and Immunity
  • Session type : Poster Session
  • FP Number : P5515

Authors : R-H Chou (Taipei,TW), Y-W Lu (Taipei,TW), P-H Huang (Taipei,TW)

Authors:
R-H Chou1 , Y-W Lu1 , P-H Huang1 , 1Taipei Veterans General Hospital, Division of Cardiology, Department of Medicine - Taipei - Taiwan ,

Citation:

Background:
Galectin-1, a ß-galactoside-binding lectin, was reported to attenuate the cardiac inflammation and ventricular remodeling after AMI. Its role in stable CAD was not fully elaborated. This study aimed to identify the relationship between galectin-1 and severity of CAD in patients with stable angina.
Methods:
Totally 834 subjects underwent elective CAG were enrolled. Pre-procedure galectin-1 and hsCRP concentrations were determined. Subjects were grouped into tertiles according to their galectin-1 concentrations. SYNTAX scores were calculated to evaluate the severity of CAD. All patients were followed until January 2019, or the occurrence of major adverse cardiovascular events (MACE).
Results:
Patients with higher galectin-1 concentrations were older and had higher prevalence of hypertension, diabetes, heart failure, and with higher levels of hsCRP and STNYAX scores. Patients with the highest tertile of galectin-1 were associated with higher risk of MACE (Fig 1A), even after adjusting age, gender, hypertension, diabetes, hemoglobin, creatinine, and LVEF (aHR: 2.13, 95% CI: 1.04-4.33, p=0.038). Gelection-1 (AUC: 0.802) showed better discriminatory performance than hsCRP (AUC: 0.696) in prediction the incidence of MACE (Fig 1B). 
Conclusion:
Serum galectin-1 levels were associated with the severity of CAD and subsequent MACE in patients with stable angina.

Tertile 1 (n=278)

Tertile 2 (n=278)

Tertile 3 (n=278)

P

Age (years)

61.0 (54.8-71.0)

67.0 (60.0-75.0)

72.0 (61.0-80.3)

<0.001

Male, n (%)

188 (67.6)

184 (66.2)

197 (70.9)

0.479

Hypertension, n (%)

153 (55.0)

185 (66.5)

219 (78.8)

<0.001

Diabetes, n (%)

67 (24.1)

90 (32.4)

123 (44.2)

<0.001

Heart failure, n (%)

10 (3.6)

8 (2.9)

44 (15.8)

<0.001

Hemoglobin (g/dL)

13.5 (12.5-14.3)

13.4 (12.4-14.3)

12.3 (10.8-13.7)

<0.001

Creatinine (mg/dL)

0.9 (0.8-1.1)

1.0 (0.9-1.2)

1.3 (1.1-1.9)

<0.001

Hs-CRP (mg/dL)

0.1 (0.0-0.2)

0.1 (0.0-0.3)

0.2 (0.1-0.7)

<0.001

Galectin 1 (ng/mL)

13.3 (10.2-14.7)

18.7 (17.4-20.5)

29.3 (25.5-38.5)

<0.001

SYNTAX score

0.0 (0.0-5.0)

0.0 (0.0-7.0)

7.0 (0.0-16.1)

<0.001

LVEF (%)

59.0 (54.6-62.2)

58.0 (52.0-63.0)

55.9 (49.0-60.9)

0.009

MACE: revascularization, n (%)

17 (6.1)

13 (4.7)

43 (15.5)

<0.001

MACE: nonfatal MI, n (%)

1 (0.4)

1 (0.4)

7 (2.5)

0.018

MACE: nonfatal stroke, n (%)

0 (0.0)

1 (0.4)

2 (0.7)

0.367

MACE: death, n (%)

4 (1.4)

1 (0.4)

13 (4.7)

0.001

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are